Eli Lil­ly dan­gles $960M for Rigel's RIPK in­hibitor, tak­ing on Sanofi and De­nali in neu­rode­gen­er­a­tion

More than two years af­ter Sanofi and De­nali signed their $1 bil­lion neu­rode­gen­er­a­tion and in­flam­ma­tion pact, they’re get­ting a deep-pock­et­ed ri­val.

Eli Lil­ly an­nounced …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER